The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer.

Autor: Cocce KJ; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA., Jasper JS; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA., Desautels TK; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA., Everett L; Department of Biological Sciences, North Carolina State University, Raleigh, NC 27695, USA., Wardell S; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA., Westerling T; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA., Baldi R; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA., Wright TM; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA., Tavares K; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA., Yllanes A; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA., Bae Y; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA., Blitzer JT; Viba Therapeutics, San Francisco, CA 94158, USA., Logsdon C; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA., Rakiec DP; Novartis Institutes for Biomedical Research, Oncology Disease Area, Cambridge, MA 02139, USA., Ruddy DA; Novartis Institutes for Biomedical Research, Oncology Disease Area, Cambridge, MA 02139, USA., Jiang T; Department of Biostatistics, Duke Cancer Institute, Duke University School of Medicine, Durham, NC 27710, USA., Broadwater G; Department of Biostatistics, Duke Cancer Institute, Duke University School of Medicine, Durham, NC 27710, USA., Hyslop T; Department of Biostatistics, Duke Cancer Institute, Duke University School of Medicine, Durham, NC 27710, USA., Hall A; Department of Pathology, Duke University School of Medicine, Durham, NC 27710, USA., Laine M; The Ben May Department for Cancer Research, The University of Chicago, Chicago, IL 60637, USA., Phung L; The Ben May Department for Cancer Research, The University of Chicago, Chicago, IL 60637, USA., Greene GL; The Ben May Department for Cancer Research, The University of Chicago, Chicago, IL 60637, USA., Martin LA; Breast Cancer Now, Toby Robins Research Centre, Institute of Cancer Research, London, SW3 6JB, UK., Pancholi S; Breast Cancer Now, Toby Robins Research Centre, Institute of Cancer Research, London, SW3 6JB, UK., Dowsett M; Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital NHS Trust, London, SW3 6JJ, UK., Detre S; Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital NHS Trust, London, SW3 6JJ, UK., Marks JR; Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA., Crawford GE; Department of Pediatrics, Duke University School of Medicine, Durham, NC 27710, USA., Brown M; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA., Norris JD; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA., Chang CY; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA., McDonnell DP; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA. Electronic address: donald.mcdonnell@duke.edu.

Publikováno v: Cell reports [Cell Rep] 2019 Oct 22; Vol. 29 (4), pp. 889-903.e10.

CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC.

Autor: Stice JP; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina., Wardell SE; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina., Norris JD; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina., Yllanes AP; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina., Alley HM; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina., Haney VO; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina., White HS; G1 Therapeutics, Inc., Research Triangle Park, North Carolina., Safi R; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina., Winter PS; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina., Cocce KJ; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina., Kishton RJ; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina., Lawrence SA; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina., Strum JC; G1 Therapeutics, Inc., Research Triangle Park, North Carolina., McDonnell DP; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina. donald.mcdonnell@duke.edu.

Publikováno v: Molecular cancer research : MCR [Mol Cancer Res] 2017 Jun; Vol. 15 (6), pp. 660-669. Date of Electronic Publication: 2017 Feb 16.